TradeFlare's AI research teams analysed AUTL on 14 market nights between April 30, 2026 and August 17, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 17, 2026 | BUY | $2.15 | $2.65 / $1.83 | +2.6% | -17.1% | The technical setup suggests a potential breakout in the near term, supported by fundamental and sentiment tailwinds. |
| August 11, 2026 | BUY | $2.11 | $3.17 / $1.58 | -1.7% | -12.9% | The post-earnings drift suggests sustained momentum that could play out over several weeks. |
| August 10, 2026 | BUY | $2.11 | $3.17 / $1.58 | +10.1% | +1.9% | The post-earnings drift suggests sustained momentum that could play out over several weeks. |
| August 7, 2026 | BUY | $2.00 | $2.30 / $1.70 | +1.9% | +6.2% | The post-earnings drift signal suggests a multi-week trend. |
| August 6, 2026 | BUY | $1.90 | $2.25 / $1.59 | +11.0% | +14.5% | The post-earnings drift signal suggests momentum may continue to build over the coming weeks. |
| May 19, 2026 | HOLD | $1.63 | — / — | +3.1% | -6.1% | Continued commercial launch success of AUCATZYL. |
| May 18, 2026 | HOLD | $1.63 | — / — | -6.7% | -17.2% | Continued commercial launch success of AUCATZYL. |
| May 8, 2026 | BUY | $1.61 | — / — | +3.8% | -7.0% | Continued positive developments and data readouts for AUCATZYL. |
| May 7, 2026 | BUY | $1.70 | $2.04 / $1.45 | -1.2% | -5.0% | The recent positive news and the potential for a breakout above resistance suggest a medium-term upward trend. |
| May 6, 2026 | BUY | $1.64 | — / — | +0.6% | -2.4% | FDA approval of AUCATZYL, a significant commercial milestone. |
| May 5, 2026 | BUY | $1.57 | — / — | -2.4% | -1.2% | Successful execution of cost-cutting measures from workforce reduction. |
| May 4, 2026 | BUY | $1.47 | $1.76 / $1.25 | +0.6% | +11.5% | The current market conditions and the stock's technical setup do not provide a clear enough signal for a buy. |
| May 1, 2026 | HOLD | $1.41 | — / — | +6.8% | +25.2% | Continued positive clinical data and guidance for AUCATZYL. |
| April 30, 2026 | BUY | $1.41 | — / — | +14.2% | +32.6% | Continued positive sentiment from analyst upgrades and retail investors. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.